Equities

ALVAL

FR0013254851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:03 2024-06-06 am EDT			5-day change	1st Jan Change
2.11 ^EUR	-2.31%		-45.90%	-57.80%

Jun. 04	Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit	MT
Jun. 04	Valbiotis: share price plummets, Nestlé agreement terminated	CF

Valbiotis Appoints Christine Roy-Duval as Director of Development and Medical Affairs

March 21, 2018 at 02:30 am EDT

Valbiotis has appointed Dr. Christine Roy-Duval as Director of Development and Medical Affairs, effective as of 1 March 2018. Prior to joining VALBIOTIS, Dr. Roy-Duval served as International Clinical Investigation Director for SANOFI's Diabetes since 2011.

Latest news about VALBIOTIS

Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit	Jun. 04	MT
Valbiotis: share price plummets, Nestlé agreement terminated	Jun. 04	CF
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Valbiotis: launch of Valbiotis PRO Cholesterol in May	Apr. 03	CF
Valbiotis: capital increase successfully completed	Dec. 22	CF
Valbiotis: 15 ME capital increase	Dec. 12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	Dec. 12	MT
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Valbiotis: share price rises on success of clinical study	23-09-12	CF
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	23-09-11	CI
VALBIOTIS : Invest Securities confirms its recommendation	23-07-17	CF
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Valbiotis: share price up, broker in support	23-05-25	CF
VALBIOTIS : Oddo BHF raises its target price	23-05-25	CF
Valbiotis: share price soars, broker adjusts target	23-05-23	CF
VALBIOTIS : promising study, Invest Sec. raises its target	23-05-23	CF
Valbiotis: 'major' breakthrough in type 2 diabetes	23-05-22	CF
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63	23-05-22	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science	23-03-13	CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing...	23-01-31
Valbiotis: encouraging results in hypertension	23-01-30	CF
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure	23-01-30	CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University	22-12-14	CI

Chart VALBIOTIS

Duration

Period

More charts

Company Profile

VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. VALBIOTIS specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. VALBIOTIS is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception VALBIOTIS has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for VALBIOTIS

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.11 EUR

Average target price

8 EUR

Spread / Average Target

+279.15%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALBIOTIS	-57.80%	37.03M
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	109B
BIONTECH SE	-3.53%	24.74B
ARGENX SE	+2.71%	22.67B
GENMAB A/S	-9.95%	18.14B
WUXI APPTEC CO., LTD.	-41.48%	16.67B
BEIGENE, LTD.	-12.62%	16.64B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.45B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.32B

Bio Therapeutic Drugs